当前位置: X-MOL 学术Expert Opin. Drug Deliv. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
A pilot study examining patient preference and satisfaction for ava®, a reusable electronic injection device to administer certolizumab pegol.
Expert Opinion on Drug Delivery ( IF 6.6 ) Pub Date : 2020-03-23 , DOI: 10.1080/17425247.2020.1736552
Bart P H Pouls 1, 2 , Lars E Kristensen 3 , Marianne Petersson 4 , B J F van den Bemt 1, 2 , Luca Ballerini 5 , Richard Bruggraber 6 , Henrik Karlen 7 , Irina Mountian 8 , Etienne van Bracht 9 , Susanne Wiegratz 10 , Tanja S Jørgensen 3
Affiliation  

Background: Anti-tumor necrosis factor (anti-TNF) adherence is suboptimal. ava®, a reusable electromechanical self-injection device (e-Device) developed for certolizumab pegol (CZP) administration, aims to overcome some barriers to increase adherence. This study evaluates patient experience of the e-Device and its training materials and determines patient device preference.Methods: CZP-treated patients were recruited from the Netherlands, Denmark and Sweden. Patients completed a pre-injection Assessment of Self-Injection (ASI) questionnaire investigating self-injection perception. After training, patients administered 3 consecutive self-injections using the e-Device, patient experience of each was assessed using the post-injection ASI. An additional questionnaire evaluated training materials. After Injection 3, patients indicated their preference: the e-Device or their previous device.Results: 59 patients participated; most rated the e-Device highly for satisfaction, self-confidence and ease of use. The (negative) feelings and pain and skin reactions domains had low ratings. Post-injection ASI domain scores were similar following each of the 3 e-Device injections. Training materials were rated highly (video: 8.4/10; step-by-step guide: 8.4/10). 57.1% (32/56) patients preferred the e-Device over their previous self-injection device.Conclusions: Patients were satisfied with the e-Device and most preferred it over other self-injection devices. By improving patient experience, the e-Device may help increase medication adherence.

中文翻译:

一项试点研究,检查患者对ava®(一种可重复使用的电子注射装置,用于施用certolizumab聚乙二醇)的喜好和满意度。

背景:抗肿瘤坏死因子(anti-TNF)依从性欠佳。ava®是一种为certolizumab聚乙二醇(CZP)给药而开发的可重复使用的机电式自我注射装置(e-Device),旨在克服一些增加依从性的障碍。这项研究评估了电子设备及其培训材料的患者体验,并确定了患者设备的偏好。方法:接受CZP治疗的患者来自荷兰,丹麦和瑞典。患者完成了一项自我注射前注射评估(ASI)调查表,以调查自我注射感知。训练后,患者使用e-Device连续进行了3次自我注射,使用注射后ASI评估了每种患者的经历。另一份问卷评估了培训材料。注射3次后,患者表明他们的偏好:结果:59例患者参加了试验。大多数人对电子设备的满意度,自信心和易用性给予高度评价。(负面)感觉,疼痛和皮肤反应域的评分较低。在3次e-Device注入之后,注入后的ASI域得分均相似。培训材料的评分很高(视频:8.4 / 10;分步指南:8.4 / 10)。57.1%(32/56)的患者比以前的自助注射设备更喜欢使用电子设备。结论:患者对电子设备感到满意,并且比其他自助注射设备更喜欢它。通过改善患者体验,电子设备可以帮助增加药物依从性。(负面)感觉,疼痛和皮肤反应域的评分较低。在3次e-Device注入之后,注入后的ASI域得分均相似。培训材料的评分很高(视频:8.4 / 10;分步指南:8.4 / 10)。57.1%(32/56)的患者比以前的自助注射设备更喜欢使用电子设备。结论:患者对电子设备感到满意,并且比其他自助注射设备更喜欢它。通过改善患者体验,电子设备可以帮助增加药物依从性。(负面)感觉,疼痛和皮肤反应域的评分较低。在3次e-Device注入之后,注入后的ASI域得分均相似。培训材料的评分很高(视频:8.4 / 10;分步指南:8.4 / 10)。57.1%(32/56)的患者比以前的自助注射设备更喜欢使用电子设备。结论:患者对电子设备感到满意,并且比其他自助注射设备更喜欢它。通过改善患者体验,电子设备可以帮助增加药物依从性。结论:患者对电子设备感到满意,并且比其他自我注射设备更喜欢它。通过改善患者体验,电子设备可以帮助增加药物依从性。结论:患者对电子设备感到满意,并且比其他自我注射设备更喜欢它。通过改善患者体验,电子设备可以帮助增加药物依从性。
更新日期:2020-03-23
down
wechat
bug